Hydralazine (hydrochloride)

Hydralazine hydrochloride is an antihypertensive agent. Hydralazine hydrochloride can inhibit mitochondrial fission and human peritoneal mesothelial cell proliferation. Hydralazine hydrochloride has immunomodulation and anti-migratory effect. Hydralazine hydrochloride activates the intrinsic pathway of apoptosis and causes DNA damage^{[1][2][3][4][5]}. IC50 & Target:IC₅₀: 9.53 mM (ROS), 1.19 mM (O₂^·-)^[1] In Vitro:Hydralazine hydrochloride (40-600 μM, 24-48 h) induces caspase-dependent apoptosis and activates mitochondrial apoptotic events in leukemic T cells^[1].
Hydralazine hydrochloride (1 μM, 40 min) prevents H₂O₂-induced mitochondrial fragmentation and depolarization in ATCC-CCL2 cells^[2].
Hydralazine hydrochloride (3-100 μg/mL, 1-5 days) inhibits human peritoneal mesothelial cell proliferation^[3]. In Vivo:Hydralazine hydrochloride (5 mg/kg, Intraperitoneal injection, once a day for 4-6 weeks) plays an immunomodulation role of pro-regeneration in Spinal cord injury mice^[4].
Hydralazine hydrochloride (14 mg/kg, supplemented in drinking water for 15 days) reduces leukocyte migration in spontaneously hypertensive and normotensive rats^[5].